



ISW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Steve J. KARLIK et al.)	Group Art Unit: 1617
Application No.: 10/763,539)	Examiner: Shaojia A. Jiang
Filed: January 26, 2004)	Confirmation No.: 9237
For: COMPOSITION FOR AND)	
TREATMENT OF DEMYELINATING)	
DISEASES AND PARALYSIS BY)	
ADMINISTRATION OF)	
REMYELINATING AGENTS)	

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, copies of the listed U.S. patents and U.S. patent application publications are not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

The listed documents on the attached form PTO-1449 were cited in the attached International Search Report dated April 11, 2006 of the corresponding International application.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.


The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Date November 28, 2006

By:


Deborah H. Yellin
Registration No. 45,904

Customer No. 21839
P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620


SECOND INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/763,539
Filing Date	January 26, 2004
First Named Inventor	Steve J. KARLIK.
Examiner Name	Shaojia A. Jiang
Attorney Docket Number	1002010-000854



U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	6,060,501	A	Wachtel et al.	05/09/2000

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	N. Tubridy et al., "THE EFFECT OF ANTI-[ALPHA]4 INTEGRIN ANTIBODY ON BRAIN LESION ACTIVITY IN MS", Neurology, Vol. 53, No. 3, pp. 466-472, August 1999.
	Franz X. Weilbach et al., "DISEASE MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS. WHAT IS ON THE HORIZON?", CNS Drugs, Vol. 11, No. 2, pp. 133-157, February 1999.
	W. A. Sheremata et al., "A SAFETY AND PHARMACOKINETIC STUDY OF INTRAVENOUS NATALIZUMAB IN PATIENTS WITH MS", Neurology, Vol. 52, No. 5, pp. 1072-1074, March 1999.
	Syed A. Rizvi et al, "OTHER THERAPY OPTIONS AND FUTURE STRATEGIES FOR TREATING PATIENTS WITH MULTIPLE SCLEROSIS", Neurology, Vol. 63, (Suppl 6), pp. S47-S54, December 2004.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.